A report on the experiences of 13 patients found that the drug had no benefit for some and that some who benefited said the ...

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

A widely available antiviral medication offers new possibilities for long Covid patients seeking relief from debilitating symptoms. Research shows extended Paxlovid treatment could help restore ...

January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including ...

Pfizer CEO highlights savings, leadership changes, and acquisition-driven growth amid significant revenue loss challenges ...

A detailed examination of how patients respond to the drug at various times and doses provides greater context to a recent ...

Brookstone Capital Management trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.9% in the fourth ...

Wedmont Private Capital lessened its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 17.7% in the fourth ...

Four in 10 Minnesotans who contracted COVID-19 reported in a new state survey that they struggled with lingering health ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

Federal science agencies have renewed and increased funding for a world-renowned digital archive of protein structures housed ...